Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

ClinGenuity Uses Artificial Intelligence Redaction Tool to Keep Big Pharma Compliant
  • USA - English


News provided by

ClinGenuity

Jul 31, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Keith Kleeman, ClinGenuity founder and CEO
Keith Kleeman, ClinGenuity founder and CEO

Cincinnati, Ohio (PRWEB) July 31, 2014 -- ClinGenuity of Cincinnati, Ohio has developed an automated redaction management service using its artificial intelligence engine to meet the growing demand for pharmaceutical clinical trial disclosure and transparency initiatives.

And big pharma has jumped on it.

Having already processed more than a half billion redactions, ClinGenuity clearly has unsurpassed experience in this critical area, said Keith Kleeman, ClinGenuity founder and CEO.

It’s simply unfair to ask a team of humans from a standard Contract Research Organization (CRO) to perform this task accurately. An average CRO does not have intelligent tools to assist the pharma industry in this critically-important task.

Post this

“We’re seeing significant growth in the market due to our unique redaction technology, workflow and service in addition to our other services and technologies,” said Kleeman. “Our clients are some of the largest and most well-respected pharmaceutical companies globally, as well as several of the founding members of TransCelerate BioPharma, Inc.”

TransCelerate BioPharma is a nonprofit organization founded in 2012 to improve people’s health worldwide by accelerating and simplifying the research and development of innovative new therapies and medicines. Members include some of the largest pharmaceutical companies in the world.

Of critical importance to pharma is determining how best to react to and be compliant with both external clinical trial transparency mandates such as European Medicines Agency’s (EMA) Policy 70, and also internal corporate transparency mandates, both of which are extremely difficult to deliver, said Kleeman. These transparency initiatives have at their core the distribution of previously confidential clinical trial data for public consumption.

However, prior to complying with transparency and disclosure initiatives and providing these documents to the public, sensitive personal and patient-protected information must first be accurately identified and securely redacted from regulatory documents, he added.

An average document for disclosure, or Clinical Study Report, is about 10,000 pages. Considering there are approximately 600 words per page, that’s an average of six million words per study report. Larger pharmaceutical companies doing the minimum to be compliant with Policy 70 would typically need to redact a minimum of 25 clinical study reports per year, or roughly 150 million words each and every year, said Kleeman.

“Finding names, email addresses, patient ID numbers and other sensitive information is like looking for a needle in a haystack,” he said. “It’s simply unfair to ask a team of humans from a standard Contract Research Organization (CRO) to perform this task accurately. An average CRO does not have intelligent tools to assist the pharma industry in this critically- important task.”

ClinGenuity’s Redaction Management Service, the pharmaceutical industry’s only automated solution, solves these problems by combining artificial intelligence with domain expert, clinically-trained quality control reviewers using proprietary secure tools that assist in managing workflow and rules associated with the transparency initiatives.

“Almost every client we’ve worked with attempted manual solutions, but quickly found that there were accidental disclosures of sensitive information.” said Kleeman. “Our model is to manage the process through the use of intelligent automation that ties rules between automation and human review so that the common failures in consistency and accuracy are alleviated.”

ClinGenuity is fast becoming the pharmaceutical industry’s gold standard for transparency and disclosure.

“Simply put, we are the most accurate and efficient solution, and as a result we greatly reduce the risk of accidental disclosure and the liability that goes along with such a mistake for our valued clients,” said Kleeman. “It’s hard to believe, but our competition is sometimes as basic and outdated as humans armed with black markers. We are excited to be such an integral part of this new era of transparency in the pharmaceutical industry, and are proud to assist our clients in this most critical endeavor.”

For more information on ClinGenuity, go to http://www.clingenuity.com or call (513) 239-6918.                                                    

Contact: Keith Kleeman
Email: kkleeman(at)clingenuity(dot)com
Phone: (513) 239-6918

About ClinGenuity:

ClinGenuity, a Cincinnati-based medical writing company using expert medical writers assigned to each project according to expertise, has the only artificially-intelligent tool in the pharmaceutical industry. ClinGenuity increases new drug and medical device development efficiencies to help reduce development cycle times and costs.

Keith Kleeman, ClinGenuity, http://www.clingenuity.com, +1 (513) 239-6918, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.